Scientists at Memorial Sloan Kettering Cancer Center (MSK) and their colleagues are shedding new light on a tumor's earliest moments—revealing how lung cells with cancer-causing mutations recruit ...

KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat. In colon cancer, the second most common cause of cancer death, such mutations ...

NSCLC is the most frequent histological subtype of lung cancer, accounting for approximately 85% of patients with lung cancer. NSCLC includes a variety of different lung cancers, most notably ...

A single genetic mutation in a lung cell can start rewriting the rules for the tissue around it almost immediately, constructing a fibrotic scaffold that helps early tumors survive before they are ...

Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was predictive of survival outcomes for patients with advanced KRAS G12C-mutated ...

Sacituzumab tirumotecan significantly reduced progression or death risk by 51% compared to chemotherapy in EGFR-mutated non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors. The ...

The addition of olaparib to neoadjuvant chemotherapy improved overall survival in BRCA-mutated breast cancer, despite no improvement in pathologic response. Adding the PARP inhibitor led to a 3-year ...

Scientists at Memorial Sloan Kettering Cancer Center (MSK) and their colleagues are shedding new light on a tumor’s earliest moments — revealing how lung cells with cancer-causing mutations recruit ...

Impact of standard vs reduced dosing of sotorasib on efficacy and toxicity in KRAS G12C–mutated advanced non-small cell lung cancer: A systematic review and meta-analysis. This is an ASCO Meeting ...